Gilead Sciences, Inc. $GILD Shares Acquired by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC significantly increased its stake in Gilead Sciences by 104.2%, owning 1,667,799 shares worth $186.9 million after purchasing 850,906 additional shares in the first quarter.
• Institutional investors now hold 83.67% of Gilead's stock, with notable increases in share ownership from firms including Price T Rowe Associates and GAMMA Investing.
• Gilead recently reported $2.01 earnings per share, exceeding estimates, and declared a quarterly dividend of $0.79 to be paid on September 29, reflecting a 2.7% dividend yield.

Voya Investment Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 104.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,667,799 shares of the biopharmaceutical company's stock after buying an additional 850,906 shares during the period. Voya Investment Management LLC owned about 0.13% of Gilead Sciences worth $186,877,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of GILD. Ariel Investments LLC lifted its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares in the last quarter. ASR Vermogensbeheer N.V. acquired a new stake in Gilead Sciences during the 1st quarter worth $11,688,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Gilead Sciences by 4.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after buying an additional 13,194 shares in the last quarter. Finally, Souders Financial Advisors acquired a new position in Gilead Sciences during the first quarter worth about $304,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Down 2.8%

Gilead Sciences stock traded down $3.31 during midday trading on Friday, reaching $114.55. The company's stock had a trading volume of 6,466,956 shares, compared to its average volume of 5,710,857. The business has a 50-day simple moving average of $114.04 and a 200-day simple moving average of $110.08. The company has a market cap of $142.13 billion, a P/E ratio of 22.82, a P/E/G ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a fifty-two week low of $81.57 and a fifty-two week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Analysts Set New Price Targets

Several research firms recently issued reports on GILD. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Finally, Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares in the company, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.